The developments in South Sudan have forced many people, especially women and children, to flee the country, and some of them ...

智通财经APP讯，都市丽人(02298)发布截至2024年12月31日止年度业绩，收入30.1亿元(人民币，下同)，同比增加9.18%;股东应占溢利1.26亿元，同比增加196.96%;每股基本盈利5.8分;拟派发末期股息每股0.5港仙。公告称，相关 ...

Regional Development Council (RDC), during a meeting on Thursday, endorsed PHP238.5 billion worth of projects for 2026. The ...

Film Industry Development Under the agreement, Film Whanganui will extend its services to Ruapehu, supporting the district’s ...

The Democratic Republic of the Congo (DRC) owes much of its global renown to its music, which reflects its cultural diversity.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

In addition, the Group's subsidiary Viva Biotech Shanghai was successfully restructured into a joint stock limited company on September 27, 2024, as the Group currently holds approximately 72.9% of ...

SUZHOU, China, March 27, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today reported 2024 annual ...

你是否曾听说过晚期癌症患者因骨转移而承受的巨大痛苦？近日，中国国家药监局药品审评中心（CDE）官网传来好消息，科伦博泰1类新药SKB107注射液获批临床，拟开发用于晚期实体瘤骨转移。这一消息让无数患者看到了希望，也让医学界对靶向放射性药物（RDC）的研发充满了期待。

中国国家药监局近日宣布，科伦博泰的1类新药SKB107注射液成功获批临床试验，预计将用于治疗晚期实体瘤伴随的骨转移现象。这一获批标志着靶向放射性核素偶联药物（RDC）在中国的发展又向前迈进了一步。

目前，江阳区已集聚一批核医疗领域创新企业，搭建多个国家级科创平台。下一步，江阳区将继续优化产业生态，加快核医疗技术研发和成果转化，着力打造具有全国影响力的核医疗产业高地，为患者带来更多创新治疗方案。